Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Now, the FDA has approved the first treatment for anemia to help MF patients. “So, OJJAARA is a JAK inhibitor. It actually targets that pathway to help with the symptoms and also with the anemia ...

Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...

This milestone... at 13:00 Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia GSK announced today that Health Canada has approved ...

Ojjaara, which is launched in the U.S., Europe, and very recently in Japan has seen quick adoption with high quarter-on-quarter growth. And in the U.S., it's maintaining its fast launch uptake ...

Oncology sales rose 94%, driven by strong patient demand for Jemperli, Ojjaara and Zejula. Jemperli added £130 million to GSK’s top line compared with £108 million in second-quarter 2024 ...

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...